Published in Cancer Weekly, February 28th, 2006
For the second quarter of fiscal 2006, Array reported revenue of $11.9 million, compared to revenue of $12.0 million for the same period in fiscal 2005. Investment in research and development for proprietary drug discovery was $7.8 million, a $2.5 million increase over the same quarter last year, due to additional preclinical and clinical development.
Array reported a net loss of $8.7 million, or $0.23 per share, for the second quarter, compared to a net loss of $4.9 million, or $0.16 per share, for the same quarter in fiscal 2005. The reported net loss...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.